AR017220A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES MICELAS IN A WATER MEDIA, PROCESS FOR THE PREPARATION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. - Google Patents
PHARMACEUTICAL COMPOSITION THAT INCLUDES MICELAS IN A WATER MEDIA, PROCESS FOR THE PREPARATION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.Info
- Publication number
- AR017220A1 AR017220A1 ARP980106453A ARP980106453A AR017220A1 AR 017220 A1 AR017220 A1 AR 017220A1 AR P980106453 A ARP980106453 A AR P980106453A AR P980106453 A ARP980106453 A AR P980106453A AR 017220 A1 AR017220 A1 AR 017220A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- surfactant
- preparation
- stable
- micelas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
Una composicion farmacéutica que consiste en micelas en un medio acuoso, en la cual las miscelas constan de un glucocorticoesteroide lipofilo y uno ysolamente un agente tensioactivo farmacéuticamente aceptable, un procedimiento para la preparacionde una composicion farmacéutica y el empleo de lacomposicion farmacéutica para la preparacion de un medicamento para el tratamiento de enfermedades alérgicas y/o inflamatorias en el tracto respiratorio o parael tratamiento de enfermedadesintestinales. Las composiciones que contienen los glucocorticosteroides lipofilos empleados en un medio acuoso son muy difícilesde disolver en agua y luego obtener una composicion estable. Se ha descubierto que disolviendo el glucocorticosteroidelipofilo en un a gente tensioactivo,preferentemente, un agente tensioactivo no ionico, se pueden obtener composiciones estables con el glucocorticosteroide en forma micelar. El uso decomposiciones estables que comprenden por ejemplo palmitato derofleponide incorpora do en micelas formadas por un agente tensioactivo causa menos irritacion enel pulmon después de inhalacion oral por pacientes humanos, que la que se manifiesta después de la inhalacion oral del mismo agentetensioactivoindependientemente.A pharmaceutical composition consisting of micelles in an aqueous medium, in which the miscelas consist of a lipophilic glucocorticoid steroid and one and only a pharmaceutically acceptable surfactant, a process for the preparation of a pharmaceutical composition and the use of the pharmaceutical composition for the preparation of a medication for the treatment of allergic and / or inflammatory diseases in the respiratory tract or for the treatment of intestinal diseases. Compositions containing lipophilic glucocorticosteroids used in an aqueous medium are very difficult to dissolve in water and then obtain a stable composition. It has been discovered that by dissolving glucocorticosteroideliprophyl in a surfactant, preferably a non-ionic surfactant, stable compositions with the glucocorticosteroid in micellar form can be obtained. The use of stable decompositions comprising, for example, derofleponide palmitate incorporated in micelles formed by a surfactant causes less irritation in the lung after oral inhalation by human patients, than that manifested after oral inhalation of the same surfactant independently.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9704833A SE9704833D0 (en) | 1997-12-22 | 1997-12-22 | New formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017220A1 true AR017220A1 (en) | 2001-08-22 |
Family
ID=20409536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106453A AR017220A1 (en) | 1997-12-22 | 1998-12-17 | PHARMACEUTICAL COMPOSITION THAT INCLUDES MICELAS IN A WATER MEDIA, PROCESS FOR THE PREPARATION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1043973A1 (en) |
| JP (1) | JP2001526210A (en) |
| KR (1) | KR20010024789A (en) |
| CN (1) | CN1283106A (en) |
| AR (1) | AR017220A1 (en) |
| AU (1) | AU1993599A (en) |
| BR (1) | BR9813811A (en) |
| CA (1) | CA2315782A1 (en) |
| EE (1) | EE200000388A (en) |
| HU (1) | HUP0102365A3 (en) |
| ID (1) | ID26945A (en) |
| IL (1) | IL136880A0 (en) |
| NO (1) | NO20003220L (en) |
| NZ (1) | NZ505073A (en) |
| PL (1) | PL341361A1 (en) |
| SE (1) | SE9704833D0 (en) |
| SK (1) | SK9532000A3 (en) |
| TR (1) | TR200001977T2 (en) |
| WO (1) | WO1999032089A1 (en) |
| ZA (1) | ZA9811461B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9902674D0 (en) * | 1999-07-12 | 1999-07-12 | Astra Ab | New composition |
| SE0000332D0 (en) * | 2000-01-31 | 2000-01-31 | Astrazeneca Ab | New use |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| SE0100901D0 (en) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | New composition |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| CA2536283A1 (en) * | 2003-08-20 | 2005-03-03 | Ajinomoto Co., Inc. | Pharmaceutical preparations having an improved solubility |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| CN100579510C (en) * | 2006-04-13 | 2010-01-13 | 新疆维吾尔自治区包虫病临床研究所 | Precursor micelle preparation and its production process |
| MX349677B (en) * | 2007-11-13 | 2017-08-08 | Meritage Pharma Inc | Corticosteroid compositions. |
| US9050368B2 (en) | 2007-11-13 | 2015-06-09 | Meritage Pharma, Inc. | Corticosteroid compositions |
| WO2010029374A1 (en) * | 2008-09-12 | 2010-03-18 | Critical Pharmaceuticals Limited | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin |
| CN101982168B (en) * | 2010-11-02 | 2012-05-23 | 山东大学 | Quercetin nano-micelle preparation and preparation method thereof |
| CN102793678B (en) * | 2011-05-26 | 2017-06-30 | 邓世明 | A kind of preparation method of the Docetaxel injection without tween |
| DE102011108948A1 (en) * | 2011-07-29 | 2013-01-31 | Achim Göpferich | Aqueous, colloidal solutions of lipophilic substances, in particular drug solutions |
| JP5456802B2 (en) * | 2012-01-23 | 2014-04-02 | 株式会社Ｃａｃ | Cell migration promoter and transdermal absorbent for wound treatment |
| WO2015008301A1 (en) * | 2013-07-17 | 2015-01-22 | Council Of Scientific & Industrial Research | Pharmaceutical composition for the treatment of diminution of bone tissue |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| KR102086316B1 (en) * | 2019-09-09 | 2020-03-09 | 한국콜마주식회사 | Cosmetic composition having excellent percutaneous absorption property |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0179583A1 (en) * | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
| US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| SA95160463B1 (en) * | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | powders for inhalation |
-
1997
- 1997-12-22 SE SE9704833A patent/SE9704833D0/en unknown
-
1998
- 1998-12-14 ZA ZA9811461A patent/ZA9811461B/en unknown
- 1998-12-17 AR ARP980106453A patent/AR017220A1/en not_active Application Discontinuation
- 1998-12-22 JP JP2000525082A patent/JP2001526210A/en active Pending
- 1998-12-22 EP EP98964662A patent/EP1043973A1/en not_active Withdrawn
- 1998-12-22 BR BR9813811-1A patent/BR9813811A/en not_active IP Right Cessation
- 1998-12-22 CN CN98812507A patent/CN1283106A/en active Pending
- 1998-12-22 WO PCT/SE1998/002426 patent/WO1999032089A1/en not_active Application Discontinuation
- 1998-12-22 NZ NZ505073A patent/NZ505073A/en unknown
- 1998-12-22 EE EEP200000388A patent/EE200000388A/en unknown
- 1998-12-22 PL PL98341361A patent/PL341361A1/en unknown
- 1998-12-22 IL IL13688098A patent/IL136880A0/en unknown
- 1998-12-22 CA CA002315782A patent/CA2315782A1/en not_active Abandoned
- 1998-12-22 AU AU19935/99A patent/AU1993599A/en not_active Abandoned
- 1998-12-22 HU HU0102365A patent/HUP0102365A3/en unknown
- 1998-12-22 SK SK953-2000A patent/SK9532000A3/en unknown
- 1998-12-22 ID IDW20001131A patent/ID26945A/en unknown
- 1998-12-22 KR KR1020007006879A patent/KR20010024789A/en not_active Application Discontinuation
- 1998-12-22 TR TR2000/01977T patent/TR200001977T2/en unknown
-
2000
- 2000-06-21 NO NO20003220A patent/NO20003220L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20003220L (en) | 2000-08-22 |
| NO20003220D0 (en) | 2000-06-21 |
| KR20010024789A (en) | 2001-03-26 |
| EE200000388A (en) | 2002-02-15 |
| HUP0102365A3 (en) | 2002-01-28 |
| JP2001526210A (en) | 2001-12-18 |
| TR200001977T2 (en) | 2000-12-21 |
| SK9532000A3 (en) | 2000-11-07 |
| SE9704833D0 (en) | 1997-12-22 |
| BR9813811A (en) | 2000-10-03 |
| NZ505073A (en) | 2002-09-27 |
| AU1993599A (en) | 1999-07-12 |
| ZA9811461B (en) | 1999-06-22 |
| IL136880A0 (en) | 2001-06-14 |
| EP1043973A1 (en) | 2000-10-18 |
| WO1999032089A1 (en) | 1999-07-01 |
| HUP0102365A2 (en) | 2001-11-28 |
| PL341361A1 (en) | 2001-04-09 |
| ID26945A (en) | 2001-02-22 |
| CN1283106A (en) | 2001-02-07 |
| CA2315782A1 (en) | 1999-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR017220A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES MICELAS IN A WATER MEDIA, PROCESS FOR THE PREPARATION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. | |
| Hassan et al. | Chemical permeation enhancers for transbuccal drug delivery | |
| KR101337578B1 (en) | Mucoadhesive xyloglucan―containing formulations useful in medical devices and in pharmaceutical formulations | |
| KR100686901B1 (en) | Medicinal compositions for application to mucosa | |
| Buajeeb et al. | Efficacy of fluocinolone acetonide gel in the treatment of oral lichen planus | |
| UA119324C2 (en) | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | |
| AR012358A1 (en) | FORMULATIONS OF PROLONGED RELEASE OF ERYTHROMYCIN DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| US20240082332A1 (en) | Method for obtaining an extract of a plant biomass | |
| BR112019026614A2 (en) | devices and methods for treating body surface disorders | |
| ES2234681T3 (en) | PHARMACEUTICAL COMPOSITION CONTAINING CICLESONIDE FOR APPLICATION TO THE MUCOSA. | |
| Holbrook et al. | Aqueous hydrocortisone mouthwash solution: clinical evaluation | |
| BR102015005689A2 (en) | VISCOSA LIQUID DOSAGE FORM AND ITS USE, PROCESS FOR PREPARING A DOSAGE FORM, LIQUID PHARMACEUTICAL COMPOSITION | |
| JP4824954B2 (en) | Oral composition for the treatment of stomatitis | |
| CA2468906A1 (en) | Use of selenite-containing compounds to be topically or buccally administered | |
| KR20150084919A (en) | Medicinal lozenge based on ibuprofen sodium dihydrate | |
| JP2012193159A (en) | Nasal spray | |
| ITBO20090775A1 (en) | COMPOSITIONS INCLUDING NON-STEROID ANTI-INFLAMMATORS | |
| ES2738652T3 (en) | Compositions of midazolam for oral administration in the treatment of seizures to obtain rapid onset of action | |
| JPS62223114A (en) | Slowly-releasing remedy for periodontosis | |
| CN115624520B (en) | Diosmin cream and application thereof | |
| Metkari et al. | Fast dissolving film: Novel drug delivery system | |
| IT201900015408A1 (en) | "EYE DROPS BASED ON A STERILIZABLE LIPOSOMIAL FORMULATION BASED ON CURCUMIN AND ITS OPHTHALMIC USE" | |
| ES2956849T3 (en) | Corticosteroid mucoadhesive pharmaceutical compositions | |
| Santosh et al. | Mucoadhesion: A Neoteric Physician's Approach | |
| EP1700597B1 (en) | Pharmaceutical composition containing in association ubidecarenone, dexpanthenol and chlorhexidine or a pharmaceutically acceptable salt thereof for cutaneous application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |